NOXA1

Summary

NOXA1 (NADPH oxidase activator 1, HGNC:10668) is a protein-coding gene on chromosome 9q34.3, encoding NADPH oxidase activator 1 (Q86UR1). Functions as an activator of NOX1, a superoxide-producing NADPH oxidase.

This gene encodes a protein which activates NADPH oxidases, enzymes which catalyze a reaction generating reactive oxygen species. The encoded protein contains four N-terminal tetratricopeptide domains and a C-terminal Src homology 3 domain. Interaction between the encoded protein and proteins in the oxidase regulatory complex occur via the tetratricopeptide domains. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 10811 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 111 total — 1 pathogenic
• MANE Select transcript: NM_001256067

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10668
Approved symbol	NOXA1
Name	NADPH oxidase activator 1
Location	9q34.3
Locus type	gene with protein product
Status	Approved
Aliases	NY-CO-31, FLJ25475
Ensembl gene	ENSG00000188747
Ensembl biotype	protein_coding
OMIM	611255
Entrez	10811

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 19 protein_coding, 1 nonsense_mediated_decay

ENST00000341349, ENST00000392815, ENST00000683555, ENST00000683683, ENST00000684693, ENST00000881438, ENST00000881439, ENST00000881440, ENST00000881441, ENST00000881442, ENST00000881443, ENST00000881444, ENST00000881445, ENST00000881446, ENST00000881447, ENST00000967001, ENST00000967002, ENST00000967003, ENST00000967004, ENST00000967005

RefSeq mRNA: 3 — MANE Select: NM_001256067 NM_001256067, NM_001256068, NM_006647

CCDS: CCDS59157, CCDS7042, CCDS94544

Canonical transcript exons

ENST00000683555 — 14 exons

Exon	Start	End
ENSE00001368295	137433965	137434079
ENSE00001370635	137429276	137429383
ENSE00001375925	137430784	137430843
ENSE00001376829	137426248	137426330
ENSE00001377770	137433205	137433263
ENSE00001378246	137428033	137428141
ENSE00001378982	137433453	137433607
ENSE00001380548	137433029	137433074
ENSE00001381232	137433750	137433864
ENSE00001382733	137431075	137431100
ENSE00001382964	137428882	137429016
ENSE00001383989	137431236	137431341
ENSE00003919708	137434224	137434406
ENSE00003920959	137423393	137423706

Expression profiles

Bgee: expression breadth ubiquitous, 229 present calls, max score 99.34.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.5364 / max 68.7528, expressed in 1137 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
99696	5.5364	1137

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	99.34	silver quality
mucosa of transverse colon	UBERON:0004991	93.21	gold quality
right uterine tube	UBERON:0001302	93.04	gold quality
right frontal lobe	UBERON:0002810	92.14	gold quality
metanephros cortex	UBERON:0010533	91.56	gold quality
adenohypophysis	UBERON:0002196	91.21	gold quality
Brodmann (1909) area 9	UBERON:0013540	90.93	gold quality
pituitary gland	UBERON:0000007	90.20	gold quality
transverse colon	UBERON:0001157	89.96	gold quality
nucleus accumbens	UBERON:0001882	89.67	gold quality
body of pancreas	UBERON:0001150	89.32	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.28	gold quality
anterior cingulate cortex	UBERON:0009835	89.07	gold quality
nasal cavity epithelium	UBERON:0005384	88.97	silver quality
right lobe of thyroid gland	UBERON:0001119	88.50	gold quality
left lobe of thyroid gland	UBERON:0001120	88.21	gold quality
mucosa of stomach	UBERON:0001199	88.18	gold quality
cerebellar hemisphere	UBERON:0002245	88.16	gold quality
caudate nucleus	UBERON:0001873	88.12	gold quality
putamen	UBERON:0001874	88.01	gold quality
cerebellar cortex	UBERON:0002129	87.98	gold quality
kidney epithelium	UBERON:0004819	87.98	silver quality
hypothalamus	UBERON:0001898	87.97	gold quality
body of stomach	UBERON:0001161	87.84	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	87.75	gold quality
left ovary	UBERON:0002119	87.41	gold quality
minor salivary gland	UBERON:0001830	87.09	gold quality
metanephros	UBERON:0000081	87.06	gold quality
cerebellum	UBERON:0002037	87.06	gold quality
lower esophagus mucosa	UBERON:0035834	86.94	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.58

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

Literature-anchored findings (GeneRIF, showing 19)

• These studies demonstrate that, in reconstituted NOX1/NOXO1/NOXA1 systems, the NOXA1 SH3 domain is not required for function but, when present, can critically modulate the activity of the enzyme system. (PMID:17602954)
• PKA-phosphorylated NoxA1 is a new binding partner of 14-3-3 protein; this forms the basis of a novel mechanism regulating the formation of ROS by Nox1 and, potentially, other NoxA1-regulated Nox family members (PMID:17913709)
• Essential role of NOXA1 in generation of reacgtive oxygen species induced by oxidized low density lipoprotein in endothelial cells is reported. (PMID:18568954)
• a novel, inhibitory function for Noxa1 in Duox1 regulation. (PMID:18606821)
• NoxA1 is the functional homolog of p67phox in vascular smooth muscle cells (VSMC) that regulates redox signaling and VSMC phenotype. (PMID:20083677)
• these results demonstrate that phosphorylation of NoxA1 is a part of the feedback mechanism that functions through activation of Rac with a net outcome of negative modulation of Nox1 activity. (PMID:20230789)
• The first quantitative characterization of the interactions made between the cytosolic regulators NOXO1 and NOXA1 and membrane-bound p22(phox), is presented. (PMID:20454568)
• Tks4 and Tks5 directly bind to NoxA1. The integrity of the N-terminal PRR of NoxA1 is essential for this direct interaction with the Tks proteins. (PMID:20609497)
• The Nox1-dependent generation of reactive oxygen species is dependent on Src phosphorylation of NoxA1 and Tks4. Blockage of phosphorylation of NoxA1 and Tks4 decreases Nox1-dependent ROS generation and blocks SrcYF-induced invadopodia formation. (PMID:20943948)
• Noxa1 has quite different kinetic properties from p67(phox) and suggest that Noxa1 may function as a moderate activator of Nox2. (PMID:22244833)
• Phosphorylation of Thr341 allows Noxo1 to sufficiently interact with Noxa1, an interaction that participates in Nox1 activation (PMID:23957209)
• A NOXA1 peptide blocked NOXA1-Nox1 binding. The finding identifies a NOXA1-activating domain and an isoform-specific Nox1 inhibitor. (PMID:24187133)
• Data from pull-down assay between the Noxo1 and Noxa1 showed that the SH3 domains (Noxa1) is responsible for interaction with Noxo1 C-terminal tail harboring proline rich region. (PMID:28625920)
• both caspase-8-dependent and -independent apoptotic mechanisms are activated in triple-negative breast cancer cells undergoing sustained endoplasmic reticulum stress. (PMID:29374147)
• mitochondrial targeting domain peptide induces necrotic cell death by interaction with the VDAC2 protein. (PMID:31285435)
• These results identify NOXA mRNA destabilization/MCL-1 adaptation as a non-genomic mechanism that limits apoptotic responses. (PMID:31727958)
• MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment. (PMID:32015503)
• MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex. (PMID:32094511)
• The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA. (PMID:32847975)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	noxa1	ENSDARG00000056047
mus_musculus	Noxa1	ENSMUSG00000036805
rattus_norvegicus	Noxa1	ENSRNOG00000009286

Paralogs (1): NCF2 (ENSG00000116701)

Protein

Protein identifiers

NADPH oxidase activator 1 — Q86UR1 (reviewed: Q86UR1)

Alternative names: Antigen NY-CO-31, NCF2-like protein, P67phox-like factor, p51-nox

All UniProt accessions (3): Q86UR1, A0A804HIB1, A0A804HJ29

UniProt curated annotations — full annotation on UniProt →

Function. Functions as an activator of NOX1, a superoxide-producing NADPH oxidase. Functions in the production of reactive oxygen species (ROS) which participate in a variety of biological processes including host defense, hormone biosynthesis, oxygen sensing and signal transduction. May also activate CYBB/gp91phox and NOX3.

Subunit / interactions. NOX1, NOXA1, NOXO1, RAC1 and CYBA forms a functional multimeric complex supporting ROS production. Interaction with YWHAZ prevents the interaction of NOXA1 with NOXO1 and RAC1 and its targeting to membranes, hence reducing its ability to activate NOX1. Interacts (via N-terminus) with SH3PXD2A and SH3PXD2B; the interaction is direct. Interacts with NCF1. Interacts with RAC1. Interacts with NOXO1. Interacts with NOX1.

Subcellular location. Cytoplasm. Cell membrane.

Tissue specificity. Widely expressed. Detected in pancreas, liver, kidney, spleen, prostate, small intestine and colon.

Post-translational modifications. Interaction with YWHAZ depends on phosphorylation by PKA.

Domain organisation. The SH3 domain mediates interaction with NOXO1 and NCF1 and has autoregulatory function. The TPR repeats mediate interaction with RAC1.

Miscellaneous. Mostly inactive for NOX1 activation. Does not interact with NOXO1. Inactive for NOX1 activation.

Similarity. Belongs to the NCF2/NOXA1 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q86UR1-1	1	yes
Q86UR1-2	2
Q86UR1-3	3, NOXA1inhib

RefSeq proteins (3): NP_001242996, NP_001242997, NP_006638 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000270	PB1_dom	Domain
IPR001452	SH3_domain	Domain
IPR011990	TPR-like_helical_dom_sf	Homologous_superfamily
IPR019734	TPR_rpt	Repeat
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR051864	NCF2_NOXA1	Family
IPR053793	PB1-like	Domain

Pfam: PF00018, PF00564

UniProt features (46 total): sequence conflict 13, mutagenesis site 10, strand 5, repeat 4, compositionally biased region 2, modified residue 2, splice variant 2, sequence variant 2, domain 2, region of interest 2, chain 1, helix 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7CFZ	X-RAY DIFFRACTION	1.89

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86UR1-F1	73.23	0.34

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 172, 461

Mutagenesis-validated functional residues (10):

Position	Phenotype
34	partial loss of function.
37	partial loss of function.
68	loss of function and loss of interaction with rac1.
103	loss of function and loss of interaction with rac1. loss of localization to membranes.
172	loss of phosphorylation. loss of interaction with yhawz; when associated with a-461.
172	constitutively interacts with ywhaz; when associated with e-461.
205	unable to activate nox2.
436	loss of interaction with noxo1 and ncf1. loss of localization to membranes. partial loss of function.
461	loss of phosphorylation. loss of interaction with yhawz; when associated with a-172.
461	constitutively interacts with ywhaz; when associated with e-172.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-5668599	RHO GTPases Activate NADPH Oxidases
R-HSA-9013149	RAC1 GTPase cycle
R-HSA-9013423	RAC3 GTPase cycle
R-HSA-9673324	WNT5:FZD7-mediated leishmania damping

MSigDB gene sets: 94 (showing top): GOBP_REGULATION_OF_RESPIRATORY_BURST, GOBP_SUPEROXIDE_METABOLIC_PROCESS, GOMF_GTPASE_BINDING, COUP_01, GOBP_REGULATION_OF_REACTIVE_OXYGEN_SPECIES_METABOLIC_PROCESS, GOBP_RESPIRATORY_BURST, GOBP_SUPEROXIDE_ANION_GENERATION, GOBP_HYDROGEN_PEROXIDE_METABOLIC_PROCESS, GOBP_REGULATION_OF_HYDROGEN_PEROXIDE_METABOLIC_PROCESS, GOBP_REACTIVE_OXYGEN_SPECIES_METABOLIC_PROCESS, KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_DN, KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_DN, GOCC_OXIDOREDUCTASE_COMPLEX, GOCC_MEMBRANE_PROTEIN_COMPLEX, GOCC_PLASMA_MEMBRANE_PROTEIN_COMPLEX

GO Biological Process (4): superoxide metabolic process (GO:0006801), regulation of hydrogen peroxide metabolic process (GO:0010310), superoxide anion generation (GO:0042554), regulation of respiratory burst (GO:0060263)

GO Molecular Function (6): superoxide-generating NADPH oxidase activator activity (GO:0016176), SH3 domain binding (GO:0017124), enzyme binding (GO:0019899), small GTPase binding (GO:0031267), identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (5): cytosol (GO:0005829), NADPH oxidase complex (GO:0043020), cytoplasm (GO:0005737), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
RHO GTPase cycle	2
RHO GTPase Effectors	1
Killing mechanisms	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein binding	2
reactive oxygen species metabolic process	1
hydrogen peroxide metabolic process	1
regulation of reactive oxygen species metabolic process	1
superoxide metabolic process	1
regulation of metabolic process	1
respiratory burst	1
enzyme activator activity	1
superoxide-generating NADPH oxidase activity	1
protein domain specific binding	1
GTPase binding	1
binding	1
cytoplasm	1
plasma membrane protein complex	1
oxidoreductase complex	1
intracellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

672 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NOXA1	CYBA	P13498	999
NOXA1	NCF1	P14598	999
NOXA1	NOXO1	Q8NFA2	999
NOXA1	NOX1	Q9Y5S8	998
NOXA1	NCF4	Q15080	995
NOXA1	NCF2	P19878	985
NOXA1	CYBB	P04839	977
NOXA1	NOX3	Q9HBY0	971
NOXA1	RAC2	P15153	941
NOXA1	AKT1	P31749	920
NOXA1	NOX4	Q9NPH5	837
NOXA1	NOX5	Q96PH1	808
NOXA1	DUOXA1	Q1HG43	775
NOXA1	DUOX1	Q9NRD9	756
NOXA1	SH3PXD2B	A1X283	746

IntAct

21 interactions, top by confidence:

A	B	Type	Score
RIMBP3	NOXA1	psi-mi:“MI:0915”(physical association)	0.670
NOXA1	RIMBP3	psi-mi:“MI:0915”(physical association)	0.670
NOXA1	NOXO1	psi-mi:“MI:0407”(direct interaction)	0.590
NOXA1	Dlg4	psi-mi:“MI:0407”(direct interaction)	0.440
NOXA1	NOXO1	psi-mi:“MI:0407”(direct interaction)	0.440
NOXO1	NOXA1	psi-mi:“MI:0407”(direct interaction)	0.440
RHOU	NOXA1	psi-mi:“MI:0915”(physical association)	0.400
NOXA1	E6	psi-mi:“MI:0915”(physical association)	0.370
CACNA1A	NOXA1	psi-mi:“MI:0915”(physical association)	0.370
EP300	NOXA1	psi-mi:“MI:0915”(physical association)	0.370
NOXO1	SOD1	psi-mi:“MI:0914”(association)	0.350
NOXA1	YWHAZ	psi-mi:“MI:0914”(association)	0.350
NOXA1	ugpB3	psi-mi:“MI:0915”(physical association)	0.000
PRKCG	NOXA1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (64): RIMBP3 (Two-hybrid), NOXA1 (Biochemical Activity), NOXA1 (Two-hybrid), NOXA1 (Reconstituted Complex), NOXA1 (Affinity Capture-RNA), NOXA1 (Two-hybrid), NOXA1 (Two-hybrid), NOXA1 (Two-hybrid), NOXA1 (Two-hybrid), NOXA1 (Two-hybrid), NOXA1 (Two-hybrid), NOXA1 (Two-hybrid), NOXA1 (Two-hybrid), NOXA1 (Two-hybrid), NOXA1 (Two-hybrid)

ESM2 similar proteins: A1L515, A4D2P6, A6QQD2, A8VU90, E1BDF2, O75808, O88995, P0CG25, P22083, Q0IIA6, Q2TA57, Q3B7L1, Q3MIP1, Q3U5Q7, Q3UR50, Q3UR97, Q3UV16, Q400G9, Q5BKX5, Q5EBM0, Q5GH72, Q5SZI1, Q5TM19, Q5U4P2, Q62994, Q659K9, Q6PRD1, Q7Z736, Q861W0, Q86UR1, Q8BNN1, Q8C0R7, Q8CG70, Q8IUW3, Q8IVL6, Q8N398, Q8NAG6, Q8NCW0, Q8R2H1, Q8VCE9

Diamond homologs: A1CEK6, A1DFN5, A2QW93, A4FU49, A4RF61, A7A261, A7E3N7, D3ZG83, F1LRS8, O42287, O55043, O60504, O94868, P10569, P19878, P29355, P32793, P38753, P39743, P43603, P49710, P52735, P62993, P62994, P80192, P87379, Q02779, Q06449, Q07883, Q08012, Q08DN7, Q0CJU8, Q0U6X7, Q14155, Q15811, Q16584, Q1E878, Q1KKW7, Q1KKZ1, Q2GT05

SIGNOR signaling

17 interactions.

A	Effect	B	Mechanism
MAPK1	down-regulates	NOXA1	phosphorylation
PRKACA	down-regulates	NOXA1	phosphorylation
PRKCA	down-regulates	NOXA1	phosphorylation
MAPK3	down-regulates	NOXA1	phosphorylation
SRC	up-regulates	NOXA1	phosphorylation
NOXA1	“down-regulates activity”	BCL2
TP53	“up-regulates quantity by expression”	NOXA1	“transcriptional regulation”
SH3PXD2B	“up-regulates activity”	NOXA1	binding
SH3PXD2A	“up-regulates activity”	NOXA1	binding
NOXO1	“up-regulates activity”	NOXA1	relocalization
NOXA1	“up-regulates activity”	NOX1	binding
NOXA1	“up-regulates activity”	NOX3	binding
PKA	“down-regulates activity”	NOXA1	phosphorylation
Gbeta	down-regulates	NOXA1	phosphorylation
ERK1/2	down-regulates	NOXA1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

111 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	83
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3238701	GRCh38/hg38 9q34.2-34.3(chr9:134288333-138155727)	Pathogenic

SpliceAI

2500 predictions. Top by Δscore:

Variant	Effect	Δscore
9:137426245:CAGGC:C	acceptor_loss	1.0000
9:137426246:AGGC:A	acceptor_loss	1.0000
9:137426247:GGC:G	acceptor_gain	1.0000
9:137426326:GCAAG:G	donor_gain	1.0000
9:137426328:AAG:A	donor_gain	1.0000
9:137426328:AAGG:A	donor_loss	1.0000
9:137426329:AG:A	donor_gain	1.0000
9:137426330:GG:G	donor_gain	1.0000
9:137426330:GGT:G	donor_loss	1.0000
9:137426331:G:GG	donor_gain	1.0000
9:137428121:TTC:T	donor_gain	1.0000
9:137428137:GGGAG:G	donor_gain	1.0000
9:137428138:GGAGG:G	donor_gain	1.0000
9:137428139:G:GT	donor_gain	1.0000
9:137428139:G:T	donor_gain	1.0000
9:137428143:T:G	donor_loss	1.0000
9:137430839:CACAG:C	donor_loss	1.0000
9:137430840:ACAG:A	donor_loss	1.0000
9:137430842:AGG:A	donor_loss	1.0000
9:137430844:GTGG:G	donor_loss	1.0000
9:137430845:T:G	donor_loss	1.0000
9:137431233:TAGGT:T	acceptor_loss	1.0000
9:137431234:A:AC	acceptor_loss	1.0000
9:137431234:A:AG	acceptor_gain	1.0000
9:137431235:G:GA	acceptor_gain	1.0000
9:137431235:GGT:G	acceptor_gain	1.0000
9:137431235:GGTC:G	acceptor_gain	1.0000
9:137431235:GGTCC:G	acceptor_gain	1.0000
9:137431340:AG:A	donor_loss	1.0000
9:137431341:GGTG:G	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000026528 (9:137429745 T>A,C), RS1000306736 (9:137434545 C>T), RS1000345084 (9:137425216 T>C), RS1000425176 (9:137434695 A>C), RS1000893816 (9:137426396 C>A,G,T), RS1000921871 (9:137432737 C>T), RS1000945725 (9:137426697 C>T), RS1001071446 (9:137422957 T>C), RS1001534838 (9:137423317 G>A), RS1001541461 (9:137427715 C>A), RS1001674453 (9:137430063 C>G,T), RS1001694961 (9:137428644 A>C,T), RS1001705491 (9:137428780 A>C,G), RS1001923666 (9:137422271 AG>A), RS1002379244 (9:137433725 C>A,T)

Disease associations

OMIM: gene MIM:611255 | disease phenotypes: MIM:610253

GenCC curated gene-disease

Mondo (1): Kleefstra syndrome 1 (MONDO:0027407)

Orphanet (1): Kleefstra syndrome (Orphanet:261494)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003487_15	Response to fenofibrate (total cholesterol levels)	4.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007806	total cholesterol change measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C563043	Kleefstra Syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases expression, affects cotreatment	3
Particulate Matter	decreases expression, increases abundance, increases expression	3
Air Pollutants	decreases expression, increases abundance, increases expression	2
Tobacco Smoke Pollution	decreases expression	2
GSK-J4	decreases expression	1
bisphenol A	affects cotreatment, decreases expression	1
decabromobiphenyl ether	affects expression	1
arsenite	decreases methylation	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
abrine	increases expression	1
jinfukang	increases expression	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	decreases expression	1
Sunitinib	increases expression	1
Acetaminophen	decreases expression	1
Cisplatin	decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Indomethacin	affects cotreatment, decreases expression	1
Phthalic Acids	increases methylation	1
Rotenone	increases expression	1
Silicon Dioxide	decreases expression	1
Thiram	decreases expression	1
Valproic Acid	decreases expression, increases methylation	1
1-Methyl-3-isobutylxanthine	affects cotreatment, decreases expression	1
1-Methyl-4-phenylpyridinium	increases expression	1
Gold Compounds	increases expression	1
Okadaic Acid	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TA89	HAP1 NOXA1 (-) 1	Cancer cell line	Male
CVCL_TA90	HAP1 NOXA1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.